Brief: United Laboratories International Announces Exclusive License Agreement With Novo Nordisk
24/03/2025 12:44
March 24 (Reuters) - United Laboratories International Holdings Ltd 3933.HK: ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK AGREEMENT FOR UBT251 UNITED BIOTECHNOLOGY IS ELIGIBLE TO RECEIVE AN UPFRONT PAYMENT OF US$200 MILLION UNITED BIOTECHNOLOGY IS ELIGIBLE TO RECEIVE POTENTIAL MILESTONE PAYMENTS OF UP TO US$1.8 BILLION Further company coverage: 3933.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million